ROS production by circulating phagocytes and Guerin carcinoma resistance to cisplatin

Authors

  • I.V. Prokhorova R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • O.I. Gorbach R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • Yu.R. Yakshibaeva R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • N.А. Shliakhtova R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • G.I. Solyanik R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology

DOI:

https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-1.15938

Keywords:

circulating phagocytes, cisplatin-resistance, phagocytic activity, pretreatment markers, ROS production

Abstract

Background: Tumor drug resistance remains a primary cause of unsuccessful cancer therapy. The search for biological markers of the sensitivity/resistance of malignant neoplasms to drug therapy is an urgent and important task, the solution of which will increase the effectiveness of anticancer chemotherapy. Aim: To study the relationship between the functional activity (parameters of the phagocytosis and reactive oxygen species (ROS) production) of neutrophils and monocytes in the peripheral blood of rats with transplanted Guerin carcinoma and the degree of its sensitivity to cisplatin (Cpt). Materials and Methods: The original and Cpt-resistant variants of Guerin carcinoma were transplanted to female Wistar rats 2.5 months old. The parameters of the phagocytic activity of circulating neutrophils and monocytes were determined by the degree of ingestion of inactivated and FITC-labeled staphylococci using flow cytometry. The number of ROS-generating cells and the intensity of ROS production by phagocytes were determined by flow cytometry using 2’,7’-dichlorodihydrofluorescein diacetate. Results: The growth of both variants of Guerin carcinoma caused a statistically significant decrease in the intensity of neutrophil phagocytosis by more than 47% with a tendency to the reduction of the intensity of phagocytosis by monocytes. The phagocytic activity of circulating neutrophils and monocytes did not differ significantly between the groups of animals with the original and Cpt-resistant variant of Guerin carcinoma. In contrast, the intensity of ROS generation by both monocytes and neutrophils in the peripheral blood of animals with Cpt-resistant tumor increased by more than 86% as compared to original carcinoma-bearing rats. Conclusion: This study provides evidence that the intensity of ROS production by circulating monocytes and neutrophils may reflect the degree of tumor sensitivity to Cpt. Increased intensity of ROS production could serve as a pretreatment predictor of the formation of tumor drug resistance.

References

Alfarouk KO, Stock CM, Taylor S, et al. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int 2015; 15: 71.

Volm M, Efferth T. Prediction of cancer drug resistance and implications for personalized medicine. Front Oncol 2015; 5: 282.

Efferth T, Konkimalla VB, Wang YF, et al. Prediction of broad-spectrum resistance of tumors towards anticancer drugs. Clin Cancer Res 2008; 14: 2405–12.

Blumenthal RD, Goldenberg DM. Methods and goals for the use of in vitro and in vivo chemosensitivity testing. Mol Biotechnol 2007; 35: 185–97.

Burstein HJ, Mangu PB, Somerfield MR, et al. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol 2011; 29: 3328–30.

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.

Vaidya A, Ayat N, Buford M, et al. Noninvasive assessment and therapeutic monitoring of drug-resistant colorectal cancer by MR molecular imaging of extradomain-B fibronectin. Theranostics 2020; 10: 11127–43.

Chae YK, Oh MS, Giles FJ. Molecular biomarkers of primary and acquired resistance to T-cell-mediated immunotherapy in cancer: landscape, clinical implications, and future directions. Oncologist 2018; 23: 410–21.

Galardi A, Colletti M, Businaro P, et al. MicroRNAs in neuroblastoma: biomarkers with therapeutic potential. Curr Med Chem 2018; 25: 584–600.

Yang WL, Lu Z, Bast RC. The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn 2017; 17: 577–91.

Liskova A, Samec M, Koklesova L, et al. Liquid biopsy is instrumental for 3PM dimensional solutions in cancer management. J Clin Med 2020; 9: 2749.

Zhao X, Zhang N, Zhang H, et al. High fibrinogen-albumin ratio index predicts poor prognosis for lung adenocarcinoma patients undergoing epidermal growth factor receptor-tyrosine kinase inhibitor treatments. Med (Baltimore) 2020; 99: e23150.

Li CC, Lin CB, Chu SC, et al. Lymphocyte percentage and platelet count correlate with the treatment outcome to tyrosine kinase inhibitors in epidermal growth factor receptor-mutated lung adenocarcinoma. Med (Baltimore) 2020; 99: e21275.

Prokhorova IV, Yurchenko OV, Pyaskovskaya ON, et al. Functional activity of circulating phagocytes as pretreatment marker of tumor drug resistance. J Biosci Med 2019; 7: 1–15.

Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 2014; 740: 364–78.

Galluzzi L, Vitale I, Michels J, et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 2014; 5: e1257.

Buhl IK, Santoni-Rugiu E, Ravn J, et al. Molecular prediction of adjuvant cisplatin efficacy in non-small cell lung cancer (NSCLC) — validation in two independent cohorts. PLoS One 2018; 13: e0194609.

Pinegin BV, Yarilin AA, Simonova AV, et al. The Use of Flow Cytometry to Assess the Functional Activity of the Human Immune System. Manual for Laboratory Doctors. Moscow 2001, 55 p. (in Russian).

Downloads

Published

26.05.2023

How to Cite

Prokhorova, I., Gorbach, O., Yakshibaeva, Y., Shliakhtova, N., & Solyanik, G. (2023). ROS production by circulating phagocytes and Guerin carcinoma resistance to cisplatin. Experimental Oncology, 43(1), 26–30. https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-1.15938

Issue

Section

Original contributions

Most read articles by the same author(s)

<< < 1 2